OneDigital Investment Advisors LLC cut its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 64.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,173 shares of the medical instruments supplier's stock after selling 20,479 shares during the period. OneDigital Investment Advisors LLC's holdings in Becton, Dickinson and Company were worth $2,559,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of BDX. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $27,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Picton Mahoney Asset Management lifted its stake in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $34,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on BDX shares. Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Raymond James Financial cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Finally, Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research note on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $219.22.
Get Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Performance
BDX traded down $3.24 during trading on Monday, hitting $172.92. 2,499,589 shares of the stock were exchanged, compared to its average volume of 2,065,561. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The stock has a fifty day moving average price of $173.94 and a two-hundred day moving average price of $207.57. The firm has a market capitalization of $49.56 billion, a P/E ratio of 33.00, a PEG ratio of 1.33 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.17 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were paid a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.41%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 79.39%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
